Hôpital St. Louis, Paris | France
Over the past 30 years, my group has dissected the pathogenesis of acute promyelocytic leukemia and the basis for therapy response. This led us to demonstrate that retinoic acid and arsenic are two targeted therapies in this malignancy, which bind and trigger the proteolytic degradation of its molecular driver, PML/RARA. We have recently demonstrated the crucial role of PML nuclear bodies in the elimination of the disease in vivo.
Keywords: Leukemia / retinoid / PML / arsenic / SUMO